UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (3), p.1630-1639

2006

Volltextzugriff (PDF)

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Oncogene, 2002-09, Vol.21 (41), p.6255-6263

2002

Volltextzugriff (PDF)

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

Cancer research (Chicago, Ill.), 2004-09, Vol.64 (18), p.6652-6659

2004

Volltextzugriff (PDF)

Inhibition of Colony-Stimulating-Factor-1 Signaling in vivo with the Orally Bioavailable cFMS Kinase Inhibitor GW2580

Proceedings of the National Academy of Sciences - PNAS, 2005-11, Vol.102 (44), p.16078-16083

2005

Volltextzugriff (PDF)

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

Bioorganic & medicinal chemistry letters, 2006-09, Vol.16 (17), p.4686-4691

2006

Volltextzugriff (PDF)

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles

Molecular cancer therapeutics, 2007-05, Vol.6 (5), p.1629-1640

2007

Volltextzugriff (PDF)

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors

Bioorganic & medicinal chemistry letters, 2009-02, Vol.19 (3), p.817-820

2009

Volltextzugriff (PDF)

The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo

Molecular cancer therapeutics, 2001-12, Vol.1 (2), p.85-94

2001

Volltextzugriff (PDF)

Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors

Bioorganic & medicinal chemistry letters, 2009-03, Vol.19 (5), p.1332-1336

2009

Volltextzugriff (PDF)

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

Cancer research (Chicago, Ill.), 2006-12, Vol.66 (23), p.11100-11105

2006

Volltextzugriff (PDF)

Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2- d]pyrimidines

Bioorganic & medicinal chemistry, 2008-11, Vol.18 (21), p.5738-5740

2008

Volltextzugriff (PDF)

Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib

Cancer research (Chicago, Ill.), 2008-01, Vol.68 (2), p.571-579

2008

Volltextzugriff (PDF)

6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases

Proceedings of the National Academy of Sciences - PNAS, 2008-02, Vol.105 (8), p.2773-2778

2008

Volltextzugriff (PDF)

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines

Molecular cancer therapeutics, 2008-04, Vol.7 (4), p.935-943

2008

Volltextzugriff (PDF)

Cloud security in a bioanalytical world: considerations for use of third-party cloud services for bioanalysis

Bioanalysis, 2023-12, Vol.15 (24), p.1461-1468

2023

Volltextzugriff (PDF)

Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors

Bioorganic & medicinal chemistry letters, 2006-05, Vol.16 (9), p.2419-2422

2006

Volltextzugriff (PDF)

Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines

Bioorganic & medicinal chemistry letters, 2003-02, Vol.13 (4), p.637-640

2003

Volltextzugriff (PDF)

A simple method for predicting serum protein binding of compounds from IC50 shift analysis for in vitro assays

Bioorganic & medicinal chemistry letters, 2004-05, Vol.14 (9), p.2309-2312

2004

Volltextzugriff (PDF)

The discovery of lapatinib (GW572016)

Molecular cancer therapeutics, 2011-11, Vol.10 (11), p.2019-2019

2011

Volltextzugriff (PDF)

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (19), p.7196-7203

2001

Volltextzugriff (PDF)

Visual Exploration of Human Motion Data

Similarity Search and Applications, p.64-71

Volltextzugriff (PDF)

Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis

Journal of medicinal chemistry, 2001-12, Vol.44 (25), p.4339-4358

2001

Volltextzugriff (PDF)

Eltrombopag, but Not Romiplostim or Thrombopoietin, Inhibits Growth of Thrombopoietin Receptor Positive and Negative Human Leukemia Cell Lines

Blood, 2012-11, Vol.120 (21), p.4726-4726

2012

Volltextzugriff (PDF)

Ligand-Binding Assays in the 21st Century Laboratory: Recommendations for an Automated Data Interchange Process

The AAPS journal, 2012-03, Vol.14 (1), p.105-112

2012

Volltextzugriff (PDF)

Ligand Binding Assays in the 21st Century Laboratory: Automation

The AAPS journal, 2012-03, Vol.14 (1), p.142-153

2012

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(76)

Publikationsform

Sprache

Englisch
(90)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(57)
Humans
(42)
Biological And Medical Sciences
(28)
Medical Sciences
(24)
Female
(21)
Animals
(17)
Pharmacology. Drug Treatments
(16)
Physical Sciences
(15)
Pharmacology & Pharmacy
(14)
Receptor, Erbb-2 - Antagonists & Inhibitors
(14)
Antineoplastic Agents
(13)
Male
(13)
Chemistry
(12)
Chemistry, Medicinal
(12)
Structure-Activity Relationship
(12)
Cell Line, Tumor
(11)
General Aspects
(11)
Mice
(11)
Oncology
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

Inhibition of Colony-Stimulating-Factor-1 Signaling in vivo with the Orally Bioavailable cFMS Kinase Inhibitor GW2580

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors

The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo

Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2- d]pyrimidines

Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib

6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines

Cloud security in a bioanalytical world: considerations for use of third-party cloud services for bioanalysis

Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors

Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines

A simple method for predicting serum protein binding of compounds from IC50 shift analysis for in vitro assays

The discovery of lapatinib (GW572016)

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer

Visual Exploration of Human Motion Data

Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis

Eltrombopag, but Not Romiplostim or Thrombopoietin, Inhibits Growth of Thrombopoietin Receptor Positive and Negative Human Leukemia Cell Lines

Ligand-Binding Assays in the 21st Century Laboratory: Recommendations for an Automated Data Interchange Process

Ligand Binding Assays in the 21st Century Laboratory: Automation

Suchergebnisse filtern